Real-world clinical outcomes and rationale for initiating abatacept as a first-line biologic for patients with anticitrullinated protein antibody- and rheumatoid factor-positive rheumatoid arthritis

Real-world clinical outcomes and rationale for initiating abatacept as a first-line biologic for patients with anticitrullinated protein antibody- and rheumatoid factor-positive rheumatoid arthritis

Aim: In rheumatoid arthritis (RA), seropositivity for both anticitrullinated protein antibody (ACPA) and rheumatoid factor (RF) is associated with disease severity and therapeutic response. Biologic (b) diseasemodifying antirheumatic drugs (DMARDs) such as abatacept are recommended after inadequat...

Full description

Saved in:
Bibliographic Details
Main Authors: Alexandrina Balanean, Cherrishe Brown-Bickerstaff, Andrew Klink, Vardhaman Patel, Hanke Zheng, Laetitia N’Dri, Keith Wittstock, Bruce Feinberg, Mark Chaballa, Vadim Khaychuk, Jill Kaufman, Prathamesh Pathak, Gordon Lam
Format: Article
Language:English
Published: Becaris Publishing Limited 2024-11-01
Series:Journal of Comparative Effectiveness Research
Subjects:
abatacept
anticitrullinated protein antibody
first-line therapy
rheumatoid arthritis
rheumatoid factor
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items